DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Monday 14 April 2014

BI 224436

Figure imgf000059_0001
Figure imgf000022_0002

(2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2- methylquinolin-3-yl)acetic acid
BI 224436
1155419-89-8  cas no
mw
442.51

3-​Quinolineacetic acid, 4-​(2,​3-​dihydropyrano[4,​3,​2-​de]​quinolin-​7-​yl)​-​α-​(1,​1-​dimethylethoxy)​-​2-​methyl-​, (αS,​4R)​-
hemi-succinate of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]
Novel hemi-succinate salt form of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid (presumed to be BI-224436) and its crystalline forms is desc in WO-2014055618.
Gilead, under license from BI, was developing BI-224436 for the oral treatment of HIV infection. In September 2011, this drug had entered phase 1 trials. Picks up from  WO2012138670, claiming a process for the preparation of the same drug. Also see the concurrently published WO2014055603.  This compound is claimed specifically in WO2009062285 and generically in WO2007131350.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
ACS Med. Chem. Lett., 2014, 5 (4), pp 422–427
DOI: 10.1021/ml500002n
Abstract Image

1H NMR: 12.4 (br, 1H), 8.52 (d, 1H, J = 4.4Hz), 7.94 (d, 1H, J = 7.9 Hz),7.65-7.61 (m, 1H), 7.45 (d,
1H, J = 8.2 Hz), 7.31-7.24 (m, 2H), 7.12 (d, 1H, J = 7.9 Hz), 6.94-6.92 (m, 1H), 4.99 (s, 1H), 4.57-4.47
(m, 2H), 3.37-3.30 (m, 2H), 2.86 (s, 3H), 0.82 (s, 9H).
13C NMR: 172.2, 158.4, 153.1, 150.1, 146.6,
146.1, 145.0, 141.0, 130.8 (br), 130.6 (br), 128.9, 128.0, 127.2, 127.1 (br) 126.4, 125.6, 118.0, 116.7,
109.1, 75.2, 70.8, 65.6, 27.7, 27.5, 24.9.
HRMS: m/z calc. for C27H26N2O4 + H+: 443.1965, m/z found:
443.1951 (-3.2 ppm).
UPLC-MS: rt = 0.68 min, m/z 443.3 [M + H]+, purity: >99.9% @ 254 nm.

read at

Sunday 13 April 2014

PTSA


ChemSpider 2D Image | p-Toluenesulfonic acid  | C7H8O3S


para-toluenesulfonic acid
p-Methylbenzenesulfonic AciD


Molecular Formula: C7H8O3

Molecular Weight: 172.2 





IH NMR

1H NMR399.65 MHz
C7 H8 O3 S0.038 g : 0.5 ml DMSO-d6
p-toluenesulfonic acid

SPECTRUM
ChemicalStructure
    Assign.     Shift(ppm)

      A             7.530
      B             7.170
      C             6.57
      D             2.302


13C NMR22.53 MHz
C7 H8 O3 S0.038 g : 0.5 ml DMSO-d6
p-toluenesulfonic acid

SPECTRUM
ChemicalStructure
       ppm   Int.  Assign.

      144.20   166      1
      138.49   213      2
      128.25  1000      3
      125.45   962      4
       20.69   437      5
  
13C NMR25.16 MHz
C7H8O3S0.35 g : 1.5 ml D2O
p-toluenesulfonic acid

SPECTRUM
ChemicalStructure
       ppm   Int.  Assign.

       142.97   306     1
       140.97   188     2
       130.15  1000     3
       126.28   886     4
        21.25   232     5


Mass
p-toluenesulfonic acid
C7H8O3S H2O         (Mass of molecular ion:    172)
   Source Temperature: 240 °C
   Sample Temperature: 140 °C
   DIRECT, 75 eV
18.0       1.2
      27.0       2.3
      28.0       1.3
      38.0       1.9
      39.0      14.2
      40.0       1.2
      41.0       4.0
      50.0       3.9
      51.0       6.7
      52.0       2.0
      53.0       2.4
      62.0       3.0
      63.0       9.7
      64.0       3.0
      65.0      31.8
      66.0       1.9
      77.0      14.8
      78.0       2.1
      79.0      15.6
      80.0       3.5
      89.0      10.4
      90.0      10.8
      91.0     100.0
      92.0       8.5
     107.0      40.6
     108.0      27.8
     109.0       2.2
     155.0       4.7
     172.0      74.4
     173.0       6.4
     174.0       3.8

ir





SEE WHAT HAPPENS ON METHYLATION
EXTRA METHYL APPEARS


Shift (ppm)
145.2128.0
132.256..5
130.221.4





FIRST SIGNAL IS Ar- CH3
second one is -OCH3

Saturday 12 April 2014

4-vinylpyridine

4-vinylpyridine 
C7H7N



1H NMR Spectrum - C7H7N









13C NMR Spectrum - C7H7N




DEPT Spectra - C7H7N







Mass






IR





Friday 11 April 2014

PROCAINE...now your nmr brush


51-05-8 Structure

PROCAINE






Explanation
a = 2 methyls

b= two sets  ie 4H NCH2

c= 2H  NCH2 TOWARDS O ATOM

d= OCH2

e= NH2

f= arom H ortho to NH2

g= arom H ortho to c=O-O SUBS










13 C NMR predictions




















DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com



AZERBAIJAN









Caucasus Mountains in northern Azerbaijan.




Image result for azerbaijan flag map







Justice for Khojaly













Bibi Heybat Mosque








///////